- Home Page
- NEWS
- EMVDA
- EURHAVAC
- OPTIMALVAC
- TRANSVAC
- Malaria - The Disease
- Press Releases
- EMVI Statutes
- Board Members and Scientific Advisory Committee Members
- Memoranda of Understanding and Intent
- EMVI Strategy
- Project Portfolio
- Annual Reports
- The Donors
- Mid-Term Review 2005
- Directives - Guidelines - Regulations
- Meeting Reports
- Procedures
- Calls
- Vacancies
Vacancy
EMVI has a vacancy for a Project Manager in connection with a project concerning vectored vaccines funded by EDCTP. Please go to Vacancies.
EMVI is very pleased to introduce Dr. Dawit Asmamaw Ejigu (MD, MSc), who commenced with EMVI on 1 June as Clinical Trial Associate dedicated to the GMZ2 Consortium. Please see under NEWS
EMVI awarded contract by EDCTP
It is with great pleasure that EMVI announces the successful outcome of an application to the European and Developing Countries' Clinical Trial Partnership (EDCTP). The project entitled "Integrating capacity building and networking in the design and conduct of Phase I and II clinical trials of viral vectored candidate malaria vaccines in East and West African children and infants", is coordinated by EMVI and has a total budget of EUR 10 671 772. The project is expected to be completed in 2013.
On 28 January 2009 an EMVI Donors Meeting was held in Brussels under the auspices of the European Commission. Discussions focused on the future of EMVI and the most appropriate legal identity to facilitate the expansion of EMVI activities, and to ensure EMVI's accountability and transparency.
CONTRIBUTIONS FROM DONORS - 2008
€ 1 500 000 - DGIS
€ 1 000 000 - Irish Aid, Republic of Ireland
€ 268 000 - Danida, Denmark
€ 456 493 for 2008 - 2009 - Sida
EMVI sends grateful thanks to its donors for their invaluable support to the important mission of EMVI.
BACKGROUND
The European Malaria Vaccine Initiative, EMVI was established in 1998 by the European Commission and interested European Union Member States, in order to address identified structural deficiencies in public funded malaria vaccine development.
The aim of EMVI is to provide a mechanism through which the development of experimental malaria vaccines can be accelerated within Europe and in developing countries.
EMVI shall facilitate and contribute financially and technically to nationally and internationally funded malaria vaccine research and development, and will provide a mechanism to see candidate molecules through to limited industrial production and clinical trials in close collaboration with the African Malaria Network Trust (AMANET).
EMVI will provide a forum for scientists and policy makers engaged in malaria vaccine research and development.
Reference: Hagan P, Bjorvatn B and Jepsen S. European Malaria Vaccine Initiative. Parasitol Today 15: 47-48, 1999